SPY393.89-3.03 -0.76%
DIA319.39+0.55 0.17%
IXIC11,264.45-270.83 -2.35%

BRIEF-Supernus Announces FDA Approval Of Qelbree For The Treatment Of ADHD In Adults

reuters.com · 04/29/2022 20:05
BRIEF-Supernus Announces FDA Approval Of Qelbree For The Treatment Of ADHD In Adults

- Supernus Pharmaceuticals Inc SUPN:

  • SUPERNUS ANNOUNCES FDA APPROVAL OF QELBREE® FOR THE TREATMENT OF ADHD IN ADULTS

  • SAYS FDA HAS NOW APPROVED QELBREE FOR TREATMENT OF ADHD IN CHILDREN (STARTING AT AGE 6), ADOLESCENTS AND ADULTS

  • SAYS AT A DAILY FLEXIBLE-DOSE BETWEEN 200MG TO 600MG, PHASE III TRIAL MET PRIMARY ENDPOINT

  • SAYS FIRST NOVEL, NONSTIMULANT OPTION FOR ADULTS WITH ADHD IN 20 YEARS

Source text for Eikon: ID:nGNX9STvyM

Further company coverage: SUPN


((Reuters.Briefs@thomsonreuters.com;))